Beam Therapeutics Reports Unregistered Equity Sale
Ticker: BEAM · Form: 8-K · Filed: Jul 3, 2025 · CIK: 1745999
| Field | Detail |
|---|---|
| Company | Beam Therapeutics Inc. (BEAM) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, unregistered-securities
TL;DR
Beam sold more stock, details TBD.
AI Summary
Beam Therapeutics Inc. announced on July 1, 2025, an unregistered sale of equity securities. The filing does not disclose the specific number of shares sold or the aggregate purchase price, but it indicates a transaction occurred under the company's existing equity distribution agreement.
Why It Matters
This filing indicates potential dilution for existing shareholders as new equity has been issued, though the specifics of the sale are not yet detailed.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can lead to dilution and lack of transparency regarding terms and pricing.
Key Players & Entities
- Beam Therapeutics Inc. (company) — Registrant
- July 01, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39208 (commission_file_number) — SEC File Number
- 857 327-8775 (phone_number) — Registrant's Telephone Number
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type of securities.
What was the date of the unregistered sale?
The earliest event reported is July 01, 2025.
Was this sale registered with the SEC?
No, the filing explicitly states 'Unregistered Sales of Equity Securities'.
Under what agreement was this sale conducted?
The filing mentions the transaction is under the company's equity distribution agreement.
What is Beam Therapeutics Inc.'s principal executive office address?
The address is 238 Main Street, Cambridge, Massachusetts, 02142.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 3, 2025 regarding Beam Therapeutics Inc. (BEAM).